101 results on '"Hassoun, Paul M."'
Search Results
2. Time Is of the Essence in PAH Therapy.
- Author
-
Naranjo, Mario and Hassoun, Paul M.
- Published
- 2021
- Full Text
- View/download PDF
3. Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension.
- Author
-
Mathai, Stephen C., Hassoun, Paul M., Puhan, Milo A., Yi Zhou, and Wise, Robert A.
- Subjects
- *
TADALAFIL , *SEX (Biology) , *DRUG efficacy , *PULMONARY hypertension treatment , *THERAPEUTICS research , *THERAPEUTICS - Abstract
The article focuses on the impact of sex in the effectiveness of tadalafil as treatment for pulmonary arterial hypertension (PAH). Topics discussed include the etiology and common treatment advised for PAH, as well as the most used method among clinical trials on determining the effectiveness of novel therapies in PAH and the influence of age, sex, baseline functional capacity and disease etiology on relevant responses to PAH-specific therapies.
- Published
- 2015
- Full Text
- View/download PDF
4. Guidelines. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases.
- Author
-
Boueiz, Adel and Hassoun, Paul M.
- Subjects
- *
PULMONARY hypertension treatment , *PULMONARY hypertension diagnosis , *CONNECTIVE tissue diseases , *MEDICAL protocols , *PULMONARY hypertension - Abstract
The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States.[1] Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
- Author
-
Chaisson, Neal F. and Hassoun, Paul M.
- Subjects
- *
SYSTEMIC scleroderma , *PULMONARY hypertension , *THERAPEUTICS , *EPIDEMIOLOGY , *PATHOLOGY - Abstract
The article provides an up-to-date, focused review of systemic sclerosis-pulmonary arterial hypertension (SSc-PAH) and how it differs from idiopathic pulmonary arterial hypertension (IPAH), including pathogenesis, appropriate screening for disease onset, and new approaches to treatment and longitudinal assessment of this disease. The epidemiology and pathogenesis of the disease are discussed.
- Published
- 2013
- Full Text
- View/download PDF
6. Acute vasoreactivity testing during right heart catheterization in chronic thromboembolic pulmonary hypertension: Results from the pulmonary vascular disease phenomics study.
- Author
-
Frantz, Robert P., Leopold, Jane A., Hassoun, Paul M., Hemnes, Anna R., Horn, Evelyn M., Mathai, Stephen C., Rischard, Franz P., Larive, A. Brett, Wilson Tang, W. h., Park, Margaret M., Hill, Nicholas S., and Rosenzweig, Erika B.
- Subjects
- *
PULMONARY hypertension , *CARDIAC catheterization , *THROMBOEMBOLISM , *PHOSPHODIESTERASE-5 inhibitors , *VASCULAR resistance ,PULMONARY artery diseases - Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is believed to involve both vascular obstruction and vasoconstriction; hence, pulmonary vasodilators such as riociguat may be beneficial. Acute vasoreactivity testing (AVT) is seldom performed routinely in CTEPH patients, so there is limited understanding of the frequency and significance of an acute vasodilator response. Systematic vasodilator testing with oxygen (O2) and oxygen plus inhaled nitric oxide (O2 + iNO) was performed as part of the Pulmonary Vascular Disease Omics (PVDOMICS) NHLBI project, providing an opportunity to examine AVT responses in CTEPH. Patients with CTEPH enrolled in PVDOMICS (n = 49, 40 with prevalent CTEPH [82%]) underwent right heart catheterization including AVT with O2 and O2 + iNO. Hemodynamics were obtained at baseline and with each challenge. Fourteen of 49 patients (29%) had >20% drop in pulmonary vascular resistance (PVR) with O2. With O2 + iNO, 30/ 49 (61%) had >20% drop in PVR, 20% had >20% drop in mean pulmonary artery pressure (mPAP) and PVR, and 8% had >10 mmHg decline in mPAP to mPAP < 40 with normal cardiac output. Patients on riociguat had less response to O2 + iNO than patients on phosphodiesterase‐5 inhibitors. Our findings shed light on the significant variability in vascular tone that is present in CTEPH, confirming that CTEPH represents a combination of mechanical obstruction and vasoconstriction that appears similar to that observed with Group 1 PAH. Additional study regarding whether results of acute vasodilator testing predict response to therapy and relate to prognosis is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading.
- Author
-
Tedford, Ryan J., Hassoun, Paul M., Mathai, Stephen C., Girgis, Reda E., Russell, Stuart D., Thiemann, David R., Cingolani, Oscar H., Mudd, James O., Borlaug, Barry A., Redfield, Margaret M., Lederer, David J., and Kass, David A.
- Subjects
- *
PULMONARY blood vessels , *PULMONARY fibrosis , *PULMONARY hypertension , *HYPERTENSION , *PULMONARY circulation - Abstract
Background--Right ventricular failure from increased pulmonary vascular loading is a major cause of morbidity and mortality, yet its modulation by disease remains poorly understood. We tested the hypotheses that, unlike the systemic circulation, pulmonary vascular resistance (RPA) and compliance (CPA) are consistently and inversely related regardless of age, pulmonary hypertension, or interstitial fibrosis and that this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ventricular pulsatile load. Methods and Results--Several large clinical databases with right heart/pulmonary catheterization data were analyzed to determine the RPA-CPA relationship with pulmonary hypertension, pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure. Patients with suspected or documented pulmonary hypertension (n= 1009) and normal pulmonary capillary wedge pressure displayed a consistent RPA-CPA hyperbolic (inverse) dependence, CPA=0.564/(0.047+RPA), with a near-constant resistance-compliance product (0.48±0.17 seconds). In the same patients, the systemic resistance-compliance product was highly variable. Severe pulmonary fibrosis (n=89) did not change the RPA-CPA relation. Increasing patient age led to a very small but statistically significant change in the relation. However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger impact, significantly lowering CPA for any RPA and negatively correlating with the resistance-compliance product (P<0.0001). Conclusions--Pulmonary hypertension and pulmonary fibrosis do not significantly change the hyperbolic dependence between RPA and CPA, and patient age has only minimal effects. This fixed relations, hip helps explain the difficulty of reducing total right ventricular afterload by therapies that have a modest impact on mean RPA. Higher pulmonary capillary wedge pressure appears to enhance net right ventricular afterload by elevating pulsatile, relative to resistive, load and may contribute to right ventricular dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Regulation of endothelial barrier function by reactive oxygen and nitrogen species
- Author
-
Boueiz, Adel and Hassoun, Paul M.
- Subjects
- *
REACTIVE oxygen species , *NITROGEN , *ENDOTHELIUM , *PATHOLOGICAL physiology - Abstract
Abstract: Excessive generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS), by activated neutrophils and endothelial cells, has been implicated in the pathophysiology of endothelial barrier dysfunction. Disruption of the integrity of this barrier markedly increases permeability to fluids, solutes and inflammatory cells and is the hallmark of many disorders such as acute lung injury (ALI) and sepsis. There has been considerable progress in our understanding of the sequence of molecular and structural events that mediate the response of endothelial cells to oxidants and nitrosants. In addition, substantial experimental evidence demonstrates improvement of endothelial barrier dysfunction with antioxidant strategies. However, no significant benefits have been observed, so far, in clinical trials of antioxidants for the treatment of endothelial barrier dysfunction. This article will review the available evidence implicating ROS and RNS in endothelial barrier dysfunction, explore potential underlying mechanisms, and identify areas of further research. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
9. Portopulmonary Hypertension.
- Author
-
Budhiraja, Rohit and Hassoun, Paul M.
- Subjects
- *
PORTAL hypertension , *PULMONARY artery - Abstract
Pulmonary involvement is common in patients with portal hypertension and can manifest in diverse manners. Changes in pulmonary arterial resistance, manifesting either as the hepatopulmonary syndrome or portopulmonary hypertension (PPHTN), have been increasingly recognized in these patients in recent years. This review summarizes the clinicopathologic features, diagnostic criteria, as well as the latest concepts in the pathogenesis and management of PPHTN, which is defined as an elevated pulmonary artery pressure in the setting of an increased pulmonary vascular resistance and a normal wedge pressure in a patient with portal hypertension. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
10. Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact.
- Author
-
Naranjo, Mario, Hassoun, Paul M., and Seravalle, Gino Seravalle
- Subjects
- *
DIAGNOSIS , *AUTOIMMUNE diseases , *DISEASE progression , *PULMONARY hypertension , *CLINICAL trials , *SYSTEMIC scleroderma - Abstract
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a catastrophic complication of one of the most common and devastating autoimmune diseases. Once diagnosed, it becomes the leading cause of mortality among this patient population. Screening modalities and risk assessments have been designed and validated by various organizations and societies in order to identify patients early in their disease course and promptly refer them to expert centers for a hemodynamic assessment and formal diagnosis. Moreover, several large multicenter clinical trials have now included patients with SSc-PAH to assess their response to therapy. Despite an improved understanding of the condition and significant advances in supportive and targeted therapy, outcomes have remained far from optimal. Therefore, rigorous phenotyping and search for novel therapies are desperately needed for this devastating condition. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension.
- Author
-
Gao, Li, Skinner, John, Nath, Tanmay, Lin, Qing, Griffiths, Megan, Damico, Rachel L., Pauciulo, Michael W., Nichols, William C., Hassoun, Paul M., Everett, Allen D., and Johns, Roger A.
- Subjects
- *
PULMONARY arterial hypertension , *RESISTIN , *OVERALL survival , *PULMONARY hypertension , *SINGLE nucleotide polymorphisms , *RIGHT ventricular hypertrophy , *BIOMARKERS - Abstract
Background: Abnormal remodeling of distal pulmonary arteries in patients with pulmonary arterial hypertension (PAH) leads to progressively increased pulmonary vascular resistance, followed by right ventricular hypertrophy and failure. Despite considerable advancements in PAH treatment prognosis remains poor. We aim to evaluate the potential for using the cytokine resistin as a genetic and biological marker for disease severity and survival in a large cohort of patients with PAH. Methods: Biospecimens, clinical, and genetic data for 1121 adults with PAH, including 808 with idiopathic PAH (IPAH) and 313 with scleroderma-associated PAH (SSc-PAH), were obtained from a national repository. Serum resistin levels were measured by ELISA, and associations between resistin levels, clinical variables, and single nucleotide polymorphism genotypes were examined with multivariable regression models. Machine-learning (ML) algorithms were applied to develop and compare risk models for mortality prediction. Results: Resistin levels were significantly higher in all PAH samples and PAH subtype (IPAH and SSc-PAH) samples than in controls (P <.0001) and had significant discriminative abilities (AUCs of 0.84, 0.82, and 0.91, respectively; P <.001). High resistin levels (above 4.54 ng/mL) in PAH patients were associated with older age (P =.001), shorter 6-min walk distance (P =.001), and reduced cardiac performance (cardiac index, P =.016). Interestingly, mutant carriers of either rs3219175 or rs3745367 had higher resistin levels (adjusted P =.0001). High resistin levels in PAH patients were also associated with increased risk of death (hazard ratio: 2.6; 95% CI: 1.27–5.33; P <.0087). Comparisons of ML–derived survival models confirmed satisfactory prognostic value of the random forest model (AUC = 0.70, 95% CI: 0.62–0.79) for PAH. Conclusions: This work establishes the importance of resistin in the pathobiology of human PAH. In line with its function in rodent models, serum resistin represents a novel biomarker for PAH prognostication and may indicate a new therapeutic avenue. ML-derived survival models highlighted the importance of including resistin levels to improve performance. Future studies are needed to develop multi-marker assays that improve noninvasive risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension.
- Author
-
Balasubramanian, Aparna, Larive, A. Brett, Horn, Evelyn M., DuBrock, Hilary M., Mehra, Reena, Jacob, Miriam S., Hemnes, Anna R., Leopold, Jane A., Radeva, Milena K., Hill, Nicholas S., Erzurum, Serpil C., Rosenzweig, Erika B., Frantz, Robert P., Rischard, Franz P., Beck, Gerald J., Hassoun, Paul M., and Mathai, Stephen C.
- Subjects
- *
QUALITY of life , *PULMONARY hypertension , *PULMONARY arterial hypertension , *PROPORTIONAL hazards models ,PULMONARY artery diseases - Abstract
Health-related quality of life (HRQOL) is frequently impaired in pulmonary arterial hypertension. However, little is known about HRQOL in other forms of pulmonary hypertension (PH). Does HRQOL vary across groups of the World Symposium on Pulmonary Hypertension (WSPH) classification system? This cross-sectional study included patients with PH from the Pulmonary Vascular Disease Phenomics (PVDOMICS) cohort study. HRQOL was assessed by using emPHasis-10 (e-10), the 36-item Medical Outcomes Study Short Form survey (physical component score [PCS] and mental component score), and the Minnesota Living with Heart Failure Questionnaire. Pearson correlations between HRQOL and demographic, physiologic, and imaging characteristics within each WSPH group were tested. Multivariable linear regressions compared HRQOL across WSPH groups, adjusting for demographic characteristics, disease prevalence, functional class, and hemodynamics. Cox proportional hazards models were used to assess associations between HRQOL and survival across WSPH groups. Among 691 patients with PH, HRQOL correlated with functional class and 6-min walk distance but not hemodynamics. HRQOL was severely depressed across WSPH groups for all measures except the 36-item Medical Outcomes Study Short Form survey mental component score. Compared with Group 1 participants, Group 2 participants had significantly worse HRQOL (e-10 score, 29 vs 24 [ P =.001]; PCS, 32.9 ± 8 vs 38.4 ± 10 [ P <.0001]; and Minnesota Living with Heart Failure Questionnaire score, 50 vs 38 [ P =.003]). Group 3 participants similarly had a worse e-10 score (31 vs 24; P <.0001) and PCS (33.3 ± 9 vs 38.4 ± 10; P <.0001) compared with Group 1 participants, which persisted in multivariable models (P <.05). HRQOL was associated in adjusted models with survival across Groups 1, 2, and 3. HRQOL was depressed in PH and particularly in Groups 2 and 3 despite less severe hemodynamics. HRQOL is associated with functional capacity, but the severity of hemodynamic disease poorly estimates the impact of PH on patients' lives. Further studies are needed to better identify predictors and treatments to improve HRQOL across the spectrum of PH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Enhanced rate of H2O2 release from bovine pulmonary artery endothelial cells induced by TGF-beta1.
- Author
-
Thannickal, Victor J. and Hassoun, Paul M.
- Subjects
- *
TUMOR necrosis factors , *PULMONARY endothelium , *FREE radicals , *PHYSIOLOGY - Abstract
Tests the hypothesis that tumor necrosis factor (TGF)-beta1 stimulation of cultured bovine pulmonary artery endothelial cells (BPAEC) induces generation of oxygen-based free radicals. Effect of TGF-beta1 on proliferation and total GSH of BPAEC; Effect on extracellular release of H2O2; Effect of diethylmaleate (DEM) on extracellular H2O2 release.
- Published
- 1993
14. Editorial: Tackling the Challenges of Systemic Sclerosis-Associated Pulmonary Hypertension: One Step Forward.
- Author
-
Hassoun, Paul M. and Shafiq, Majid
- Subjects
- *
SYSTEMIC scleroderma , *PULMONARY hypertension diagnosis , *HEALTH outcome assessment , *RESEARCH funding , *RISK assessment , *PHENOTYPES , *TREATMENT effectiveness , *SEVERITY of illness index , *PROGNOSIS - Abstract
The authors comment on the meta-analysis conducted by G. Lefèvre and colleagues of all available cohort studies in which survival and/or prognostic factors in systemic sclerosis (SSc)-associated pulmonary hypertension (PH) were reported. The team of Lefèvre also calculated pooled survival rates for a total of 2,244 patients and found the prognostic significance of mean pulmonary artery pressure (mPAP) in such patients. The methods used for the meta-analysis are also discussed.
- Published
- 2013
- Full Text
- View/download PDF
15. Pulmonary arterial hypertension in china: promising news and some surprises.
- Author
-
Hassoun PM and Hassoun, Paul M
- Published
- 2011
- Full Text
- View/download PDF
16. Pulmonary Arterial Hypertension in China.
- Author
-
Hassoun, Paul M.
- Subjects
- *
LUNG diseases , *PULMONARY hypertension ,PULMONARY artery diseases - Abstract
The author comments on a study by R. Zhang and colleagues which investigated the survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. He considers the study as the largest analysis of Chinese patients with the disease and that the researchers should be commended for their work. He also cites the relevance of the study from several viewpoints. Several important findings of the study are also cited.
- Published
- 2011
- Full Text
- View/download PDF
17. A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
- Author
-
Ameri, Pietro, Mercurio, Valentina, Pollesello, Piero, Anker, Markus S., Backs, Johannes, Bayes‐Genis, Antoni, Borlaug, Barry A., Burkhoff, Daniel, Caravita, Sergio, Chan, Stephen Y., de Man, Frances, Giannakoulas, George, González, Aránzazu, Guazzi, Marco, Hassoun, Paul M., Hemnes, Anna R., Maack, Cristoph, Madden, Brendan, Melenovsky, Vojtech, and Müller, Oliver J.
- Subjects
- *
PULMONARY circulation , *PULMONARY arterial hypertension , *HEART failure , *PULMONARY hypertension - Abstract
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH‐LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH‐LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH‐LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre‐clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early‐stage development of candidate therapies for PH‐LHF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Occult right ventricular dysfunction and right ventricular-vascular uncoupling in left ventricular assist device recipients.
- Author
-
Scheel, Paul J, Cubero Salazar, Ilton M., Friedman, Samuel, Haber, Leora, Mukherjee, Monica, Kauffman, Matthew, Weller, Alexandra, Alkhunaizi, Fatimah, Gilotra, Nisha A., Sharma, Kavita, Kilic, Ahmet, Hassoun, Paul M., Cornwell, William K., Tedford, Ryan J., and Hsu, Steven
- Subjects
- *
RIGHT ventricular dysfunction , *HEART assist devices , *OCCULTISM , *PULMONARY artery , *HEART failure - Abstract
Detecting right heart failure post left ventricular assist device (LVAD) is challenging. Sensitive pressure-volume loop assessments of right ventricle (RV) contractility may improve our appreciation of post-LVAD RV dysfunction. Thirteen LVAD patients and 20 reference (non-LVAD) subjects underwent comparison of echocardiographic, right heart cath hemodynamic, and pressure-volume loop-derived assessments of RV contractility using end-systolic elastance (Ees), RV afterload by effective arterial elastance (Ea), and RV-pulmonary arterial coupling (ratio of Ees/Ea). LVAD patients had lower RV Ees (0.20 ± 0.08 vs 0.30 ± 0.15 mm Hg/ml, p = 0.01) and lower RV Ees/Ea (0.37 ± 0.14 vs 1.20 ± 0.54, p < 0.001) versus reference subjects. Low RV Ees correlated with reduced RV septal strain, an indicator of septal contractility, in both the entire cohort (r = 0.68, p = 0.004) as well as the LVAD cohort itself (r = 0.78, p = 0.02). LVAD recipients with low RV Ees/Ea (below the median value) demonstrated more clinical heart failure (71% vs 17%, p = 0.048), driven by an inability to augment RV Ees (0.22 ± 0.11 vs 0.19 ± 0.02 mm Hg/ml, p = 0.95) to accommodate higher RV Ea (0.82 ± 0.38 vs 0.39 ± 0.08 mm Hg/ml, p = 0.002). Pulmonary artery pulsatility index (PAPi) best identified low baseline RV Ees/Ea (≤0.35) in LVAD patients ((area under the curve) AUC = 0.80); during the ramp study, change in PAPi also correlated with change in RV Ees/Ea (r = 0.58, p = 0.04). LVAD patients demonstrate occult intrinsic RV dysfunction. In the setting of excess RV afterload, LVAD patients lack the RV contractile reserve to maintain ventriculo-vascular coupling. Depression in RV contractility may be related to LVAD left ventricular unloading, which reduces septal contractility. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
- Author
-
Shlobin, Oksana A., Shen, Eric, Wort, Stephen J., Piccari, Lucilla, Scandurra, John A., Hassoun, Paul M., Nikkho, Sylvia M., and Nathan, Steven D.
- Subjects
- *
PULMONARY hypertension , *DRUG development , *DISEASE management , *INTERSTITIAL lung diseases , *RESEARCH institutes ,PULMONARY artery diseases - Abstract
Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until recently, the studies of pulmonary vasodilator therapy in PH‐ILD have been largely disappointing, with some even demonstrating the potential for harm. This paper is part of a series of Consensus Statements from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative for Group 3 Pulmonary Hypertension, with prior publications covering pathogenesis, prevalence, clinical features, phenotyping, clinical trials, and impact of PH‐ILD. It offers a comprehensive review of and a holistic approach to treatment of PH‐ILD, including the management of underlying interstitial lung diseases, importance of treating the comorbidities, emphasis on importance of exercise and palliation of dyspnea, and review of the most up‐to‐date guidelines for referral for potential lung transplant work up. It also summarizes the prior, ongoing, and possibly future studies in treatment of the vascular derangement of this morbid condition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Metabolomic Differences in Connective Tissue Disease–Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
- Author
-
Simpson, Catherine E., Hemnes, Anna R., Griffiths, Megan, Grunig, Gabriele, Tang, W. H. Wilson, Garcia, Joe G. N., Barnard, John, Comhair, Suzy A., Damico, Rachel L., Mathai, Stephen C., and Hassoun, Paul M.
- Subjects
- *
LIPID metabolism , *PULMONARY arterial hypertension , *BLOOD pressure , *PULMONARY circulation , *METABOLOMICS , *RIGHT heart ventricle , *MACHINE learning , *REGRESSION analysis , *PULMONARY artery , *CONNECTIVE tissue diseases , *VASODILATORS , *SEX hormones , *RESEARCH funding , *PHENOTYPES , *LONGITUDINAL method , *ALGORITHMS , *FATTY acids , *DISEASE complications - Abstract
Objective: Patients with connective tissue disease–associated pulmonary arterial hypertension (CTD‐PAH) experience worse survival and derive less benefit from pulmonary vasodilator therapies than patients with idiopathic PAH (IPAH). We sought to identify differential metabolism in patients with CTD‐PAH versus patients with IPAH that might underlie these observed clinical differences. Methods: Adult participants with CTD‐PAH (n = 141) and IPAH (n = 165) from the Pulmonary Vascular Disease Phenomics (PVDOMICS) study were included. Detailed clinical phenotyping was performed at cohort enrollment, including broad‐based global metabolomic profiling of plasma samples. Participants were followed prospectively for ascertainment of outcomes. Supervised and unsupervised machine learning algorithms and regression models were used to compare CTD‐PAH versus IPAH metabolomic profiles and to measure metabolite‐phenotype associations and interactions. Gradients across the pulmonary circulation were assessed using paired mixed venous and wedged samples in a subset of 115 participants. Results: Metabolomic profiles distinguished CTD‐PAH from IPAH, with patients with CTD‐PAH demonstrating aberrant lipid metabolism with lower circulating levels of sex steroid hormones and higher free fatty acids (FAs) and FA intermediates. Acylcholines were taken up by the right ventricular–pulmonary vascular (RV‐PV) circulation, particularly in CTD‐PAH, while free FAs and acylcarnitines were released. In both PAH subtypes, dysregulated lipid metabolites, among others, were associated with hemodynamic and RV measurements and with transplant‐free survival. Conclusions: CTD‐PAH is characterized by aberrant lipid metabolism that may signal shifted metabolic substrate utilization. Abnormalities in RV‐PV FA metabolism may imply a reduced capacity for mitochondrial beta oxidation within the diseased pulmonary circulation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension.
- Author
-
Lowery, Megan M., Hill, Nicholas S., Wang, Lu, Rosenzweig, Erika B., Bhat, Aparna, Erzurum, Serpil, Finet, J. Emanuel, Jellis, Christine L., Kaur, Sunjeet, Kwon, Deborah H., Nawabit, Rawan, Radeva, Milena, Beck, Gerald J., Frantz, Robert P., Hassoun, Paul M., Hemnes, Anna R., Horn, Evelyn M., Leopold, Jane A., Rischard, Franz P., and Mehra, Reena
- Subjects
- *
PULMONARY arterial hypertension , *RIGHT ventricular dysfunction , *OVERALL survival , *PROPORTIONAL hazards models ,PULMONARY artery diseases - Abstract
Group 1 pulmonary arterial hypertension (PAH) is a progressive fatal condition characterized by right ventricular (RV) failure with worse outcomes in connective tissue disease (CTD). Obstructive sleep apnea and sleep-related hypoxia may contribute to RV dysfunction, though the relationship remains unclear. The aim of this study was to prospectively evaluate the association of the apnea-hypopnea index (AHI) and sleep-related hypoxia with RV function and survival. Pulmonary Vascular Disease Phenomics (National Heart, Lung, and Blood Institute) cohort participants (patients with group 1 PAH, comparators, and healthy control participants) with sleep studies were included. Multimodal RV functional measures were examined in association with AHI and percentage of recording time with oxygen saturation <90% (T90) per 10-unit increment. Linear models, adjusted for demographics, oxygen, diffusing capacity of the lungs for carbon monoxide, pulmonary hypertension medications, assessed AHI and T90, and RV measures. Log-rank test/Cox proportional hazards models adjusted for demographics, oxygen, and positive airway pressure were constructed for transplantation-free survival analyses. Analysis included 186 participants with group 1 PAH with a mean age of 52.6 ± 14.1 years; 71.5% were women, 80.8% were Caucasian, and there were 43 events (transplantation or death). AHI and T90 were associated with decreased RV ejection fraction (on magnetic resonance imaging), by 2.18% (−2.18; 95% CI: −4.00 to −0.36; P = 0.019) and 0.93% (−0.93; 95% CI: −1.47 to −0.40; P < 0.001), respectively. T90 was associated with increased RV systolic pressure (on echocardiography), by 2.52 mm Hg (2.52; 95% CI: 1.61 to 3.43; P < 0.001); increased mean pulmonary artery pressure (on right heart catheterization), by 0.27 mm Hg (0.27; 95% CI: 0.05 to 0.49; P = 0.019); and RV hypertrophy (on electrocardiography), 1.24 mm (1.24; 95% CI: 1.10 to 1.40; P < 0.001). T90, but not AHI, was associated with a 17% increased 5-year risk for transplantation or death (HR: 1.17; 95% CI: 1.07 to 1.28). In non-CTD-associated PAH, T90 was associated with a 21% increased risk for transplantation or death (HR: 1.21; 95% CI: 1.08 to 1.34). In CTD-associated PAH, T90 was associated with RV dysfunction, but not death or transplantation. Sleep-related hypoxia was more strongly associated than AHI with measures of RV dysfunction, death, or transplantation overall and in group 1 non-CTD-associated PAH but only with RV dysfunction in CTD-associated PAH. (Pulmonary Vascular Disease Phenomics Program [PVDOMICS]; NCT02980887) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Trials and Tribulations of Therapies for the Acute Respiratory Distress Syndrome.
- Author
-
Damarla, Mahendra and Hassoun, Paul M.
- Subjects
- *
RESPIRATORY insufficiency , *PROTEIN kinase inhibitors , *ARTIFICIAL respiration , *ADULT respiratory distress syndrome - Abstract
A letter to the editor is presented in response to the article "A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome."
- Published
- 2016
- Full Text
- View/download PDF
23. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
- Author
-
Simpson, Catherine E., Damico, Rachel L., Hassoun, Paul M., Martin, Lisa J., Yang, Jun, Nies, Melanie K., Vaidya, R. Dhananjay, Brandal, Stephanie, Pauciulo, Michael W., Austin, Eric D., Ivy, D. Dunbar, Nichols, William C., and Everett, Allen D.
- Subjects
- *
PULMONARY hypertension , *HEART failure , *AKAIKE information criterion , *LIKELIHOOD ratio tests , *BIOMARKERS , *NEPRILYSIN , *ENDOTHELIN receptors , *LEFT heart ventricle , *RESEARCH , *RESEARCH methodology , *PROTEIN precursors , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *ENZYME-linked immunosorbent assay , *RESEARCH funding , *HEART physiology , *PEPTIDE hormones , *STROKE volume (Cardiac output) , *PEPTIDES , *DISEASE complications - Abstract
Background: Three biomarkers, soluble suppression of tumorigenicity 2 (ST2), galectin 3 (Gal3), and N-terminal brain natriuretic peptide prohormone (NT-proBNP), are approved for noninvasive risk assessment in left-sided heart failure, and small observational studies have shown their prognostic usefulness in heterogeneous pulmonary hypertension cohorts. We examined associations between these biomarkers and disease severity and survival in a large cohort of patients with pulmonary arterial hypertension (PAH) (ie, group 1 pulmonary hypertension). We hypothesized that additive use of biomarkers in combination would improve the prognostic value of survival models.Methods: Biomarker measurements and clinical data were obtained from 2,017 adults with group 1 PAH. Associations among biomarker levels and clinical variables, including survival times, were examined with multivariable regression models. Likelihood ratio tests and the Akaike information criterion were used to compare survival models.Results: Higher ST2 and NT-proBNP were associated with higher pulmonary pressures and vascular resistance and lower 6-min walk distance. Higher ST2 and NT-proBNP levels were associated with increased risk of death (hazard ratios: 2.79; 95% CI, 2.21-3.53; P < .001 and 1.84; 95% CI, 1.62-2.10; P < .001, respectively). The addition of ST2 to survival models composed of other predictors of survival, including NT-proBNP, significantly improved model fit and predictive capacity.Conclusions: ST2 and NT-proBNP are strong, noninvasive prognostic biomarkers in PAH. Despite its prognostic value in left-sided heart failure, Gal3 was not predictive in PAH. Adding ST2 to survival models significantly improves model predictive capacity. Future studies are needed to develop multimarker assays that improve noninvasive risk stratification in PAH. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
24. Quantifying 4D flow cardiovascular magnetic resonance vortices in patients with pulmonary hypertension: A pilot study.
- Author
-
Borhani, Ali, Porter, Kristin K., Umair, Muhammad, Chu, Linda C., Mathai, Stephen C., Kolb, Todd M., Damico, Rachel L., Hassoun, Paul M., Kamel, Ihab R., and Zimmerman, Stefan L.
- Subjects
- *
PULMONARY hypertension , *MAGNETIC resonance , *HYPERTENSION , *SPHEROMAKS , *ROTATIONAL flow - Abstract
In this 4D flow cardiovascular magnetic resonance (CMR) study, vortical blood flow in the main pulmonary artery (MPA) is quantified using circulation (ᴦ), a metric used in fluid dynamics to quantify the rotational components of flow. Circulation (ᴦ) is a 4D flow CMR metric that quantifies the vortical blood flow pattern in the MPA of patients with pulmonary hypertension (PH), distinguishes them from healthy controls, and shows high correlation with invasive markers of PH severity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Prediction of Pulmonary Artery Pressure.
- Author
-
Fisher, Micah R. and Hassoun, Paul M.
- Subjects
- *
LETTERS to the editor , *PULMONARY artery - Abstract
A letter to the editor is presented in response to the article "Prediction of Pulmonary Artery Pressure" published in the previous issue.
- Published
- 2005
- Full Text
- View/download PDF
26. Xanthine oxidoreductase gene polymorphisms are associated with high risk of sepsis and organ failure.
- Author
-
Gao, Li, Rafaels, Nicholas, Dudenkov, Tanda M., Damarla, Mahendra, Damico, Rachel, Maloney, James P., Moss, Marc, Martin, Greg S., Sevransky, Jonathan, Shanholtz, Carl, Herr, Dan L., Garcia, Joe G.N., Hernandez-Beeftink, Tamara, Villar, Jesús, Flores, Carlos, Beaty, Terri H., Brower, Roy, Hassoun, Paul M., and Barnes, Kathleen C.
- Subjects
- *
GENETIC polymorphisms , *SEPSIS , *ADULT respiratory distress syndrome , *SINGLE nucleotide polymorphisms , *XANTHINE - Abstract
Background: Sepsis and associated organ failures confer substantial morbidity and mortality. Xanthine oxidoreductase (XOR) is implicated in the development of tissue oxidative damage in a wide variety of respiratory and cardiovascular disorders including sepsis and sepsis-associated acute respiratory distress syndrome (ARDS). We examined whether single nucleotide polymorphisms (SNPs) in the XDH gene (encoding XOR) might influence susceptibility to and outcome in patients with sepsis. Methods: We genotyped 28 tag SNPs in XDH gene in the CELEG cohort, including 621 European American (EA) and 353 African American (AA) sepsis patients. Serum XOR activity was measured in a subset of CELEG subjects. Additionally, we assessed the functional effects of XDH variants utilizing empirical data from different integrated software tools and datasets. Results: Among AA patients, six intronic variants (rs206805, rs513311, rs185925, rs561525, rs2163059, rs13387204), in a region enriched with regulatory elements, were associated with risk of sepsis (P < 0.008–0.049). Two out of six SNPs (rs561525 and rs2163059) were associated with risk of sepsis-associated ARDS in an independent validation cohort (GEN-SEP) of 590 sepsis patients of European descent. Two common SNPs (rs1884725 and rs4952085) in tight linkage disequilibrium (LD) provided strong evidence for association with increased levels of serum creatinine (Padjusted<0.0005 and 0.0006, respectively), suggesting a role in increased risk of renal dysfunction. In contrast, among EA ARDS patients, the missense variant rs17011368 (I703V) was associated with enhanced mortality at 60-days (P < 0.038). We found higher serum XOR activity in 143 sepsis patients (54.5 ± 57.1 mU/mL) compared to 31 controls (20.9 ± 12.4 mU/mL, P = 1.96 × 10− 13). XOR activity was associated with the lead variant rs185925 among AA sepsis patients with ARDS (P < 0.005 and Padjusted<0.01). Multifaceted functions of prioritized XDH variants, as suggested by various functional annotation tools, support their potential causality in sepsis. Conclusions: Our findings suggest that XOR is a novel combined genetic and biochemical marker for risk and outcome in patients with sepsis and ARDS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Low‐affinity insulin‐like growth factor binding protein 7 and its association with pulmonary arterial hypertension severity and survival.
- Author
-
Torres, Guillermo, Lancaster, Andrew C., Yang, Jun, Griffiths, Megan, Brandal, Stephanie, Damico, Rachel, Vaidya, Dhananjay, Simpson, Catherine E., Martin, Lisa J., Pauciulo, Michael W., Nichols, William C., Ivy, David D., Austin, Eric D., Hassoun, Paul M., and Everett, Allen D.
- Abstract
Insulin‐like growth factor (IGF) binding proteins (IGFBPs) are a family of growth factor modifiers, some of which are known to be independently associated with pulmonary arterial hypertension (PAH) survival. IGF factor binding protein 7 (IGFBP7) is a unique low‐affinity IGFBP that, independent of IGF, stimulates prostacyclin production. This study proposed to establish associations between IGFBP7 and PAH severity and survival, using enrollment and longitudinal samples. Serum IGFBP7 levels were significantly elevated in patients with PAH compared to controls. After adjusting for age and sex, logarithmic increases in IGFBP7 were associated with a 20 m shorter six‐minute walk distance (6MWD; p < 0.001), a 2−3 mmHg higher mean right atrial pressure (p < 0.001 and 0.02), and a higher likelihood of a greater REVEAL 2.0 risk category placement (p < 0.001). Kaplan−Meier analysis demonstrated significantly decreased survival with IGFBP7 above the median and Cox multivariable analysis adjusted for age and sex, demonstrated higher serum IGFBP7 was an independent predictor of survival. Though the exact mechanism is still unknown, given IGFBP7's role as a prostacyclin stimulant, it has potential use as a therapeutic target for disease modulation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Spatial and temporal resolution of metabolic dysregulation in the Sugen hypoxia model of pulmonary hypertension.
- Author
-
Simpson, Catherine E., Ambade, Anjira S., Harlan, Robert, Roux, Aurelie, Graham, David, Klauer, Neal, Tuhy, Tijana, Kolb, Todd M., Suresh, Karthik, Hassoun, Paul M., and Damico, Rachel L.
- Subjects
- *
PULMONARY hypertension , *SPATIAL resolution , *TIME series analysis , *HYPOXEMIA , *PULMONARY arterial hypertension - Abstract
Although PAH is partially attributed to disordered metabolism, previous human studies have mostly examined circulating metabolites at a single time point, potentially overlooking crucial disease biology. Current knowledge gaps include an understanding of temporal changes that occur within and across relevant tissues, and whether observed metabolic changes might contribute to disease pathobiology. We utilized targeted tissue metabolomics in the Sugen hypoxia (SuHx) rodent model to investigate tissue-specific metabolic relationships with pulmonary hypertensive features over time using regression modeling and time-series analysis. Our hypotheses were that some metabolic changes would precede phenotypic changes, and that examining metabolic interactions across heart, lung, and liver tissues would yield insight into interconnected metabolic mechanisms. To support the relevance of our findings, we sought to establish links between SuHx tissue metabolomics and human PAH -omics data using bioinformatic predictions. Metabolic differences between and within tissue types were evident by Day 7 postinduction, demonstrating distinct tissue-specific metabolism in experimental pulmonary hypertension. Various metabolites demonstrated significant tissue-specific associations with hemodynamics and RV remodeling. Individual metabolite profiles were dynamic, and some metabolic shifts temporally preceded the emergence of overt pulmonary hypertension and RV remodeling. Metabolic interactions were observed such that abundance of several liver metabolites modulated lung and RV metabolite-phenotype relationships. Taken all together, regression analyses, pathway analyses and time-series analyses implicated aspartate and glutamate signaling and transport, glycine homeostasis, lung nucleotide abundance, and oxidative stress as relevant to early PAH pathobiology. These findings offer valuable insights into potential targets for early intervention in PAH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study.
- Author
-
Naranjo, Mario, Rosenzweig, Erika B., Hemnes, Anna R., Jacob, Miriam, Desai, Ankit, Hill, Nicholas S., Larive, A. Brett, Finet, J. Emanuel, Leopold, Jane, Horn, Evelyn, Frantz, Robert, Rischard, Franz, Erzurum, Serpil, Beck, Gerald, Mathai, Stephen C., and Hassoun, Paul M.
- Subjects
- *
PULMONARY arterial hypertension , *SURVIVAL rate , *PULMONARY hypertension , *CONNECTIVE tissue diseases , *PULMONARY artery ,PULMONARY artery diseases - Abstract
The prevalence of acute vasodilator response (AVR) to inhaled nitric oxide (iNO) during right heart catheterization (RHC) is 12% in idiopathic pulmonary arterial hypertension (IPAH). AVR, however, is reportedly lower in other disease-associated pulmonary arterial hypertension (PAH), such as connective tissue disease (CTD). The prevalence of AVR in patients on PAH therapy (prevalent cases) is unknown. We sought to determine AVR prevalence in Group 1 PH in the PVDOMICS cohort of incident and prevalent patients undergoing RHC. AVR was measured in response to 100% O2 and O2 plus iNO, with positivity defined as (1) decrease in mean pulmonary artery pressure (mPAP) by ≥10 mmHg to a value ≤40 mmHg, with no change or an increase in cardiac output (definition 1); or (2) decrease in mPAP by ≥12% and pulmonary vascular resistance by ≥30% (definition 2). AVR rates and cumulative survival were compared between incident and prevalent patients. In 338 mainly prevalent (86%) patients, positive AVR to O2-only was <2%, and 5.1% to 16.9%, based on definition 1 and 2 criteria, respectively; following O2 + iNO. IPAH AVR prevalence (4.1%-18.7%) was similar to prior reports. AVR positivity was 7.7% to 15.4% in mostly CTD-PAH prevalent cases, and 2.6% to 11.8% in other PAH groups. Survival was 89% in AVR responders versus 77% in nonresponders from PAH diagnosis, and 91% versus 86% from PVDOMICS enrollment (log-rank test p = 0.04 and p = 0.05, respectively). In conclusion, AVR in IPAH patients is similar to prior studies. AVR in non-IPAH patients was higher than previously reported. The relationship between PAH therapy, AVR response, and survival warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension.
- Author
-
Simpson, Catherine E., Coursen, Julie, Hsu, Steven, Gough, Ethan K., Harlan, Robert, Roux, Aurelie, Aja, Susan, Graham, David, Kauffman, Matthew, Suresh, Karthik, Tedford, Ryan J., Kolb, Todd M., Mathai, Stephen C., Hassoun, Paul M., and Damico, Rachel L.
- Subjects
- *
PULMONARY arterial hypertension , *NUCLEOTIDE synthesis , *CONTRACTILITY (Biology) , *POSITIVE pressure ventilation , *EXERCISE tests , *CARDIAC catheterization , *PEPTIDES , *AMINO acids - Abstract
Right ventricular (RV) adaptation is the principal determinant of outcomes in pulmonary arterial hypertension (PAH), however, RV function is challenging to assess. RV responses to hemodynamic stressors are particularly difficult to interrogate without invasive testing. This study sought to identify metabolomic markers of in vivo right ventricular function and exercise performance in PAH. Consecutive subjects with PAH (n = 23) underwent rest and exercise right heart catheterization with multibeat pressure volume loop analysis. Pulmonary arterial blood was collected at rest and during exercise. Mass spectrometry-based targeted metabolomics were performed, and metabolic associations with hemodynamics and comprehensive measures of RV function were determined using sparse partial least squares regression. Metabolite profiles were compared with N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) measurements for accuracy in modeling ventriculo-arterial parameters. Thirteen metabolites changed in abundance with exercise, including metabolites reflecting increased arginine bioavailability, precursors of catecholamine and nucleotide synthesis, and branched-chain amino acids. Higher resting arginine bioavailability predicted more favorable exercise hemodynamics and pressure-flow relationships. Subjects with more severe PAH augmented arginine bioavailability with exercise to a greater extent than subjects with less severe PAH. We identified relationships between kynurenine pathway metabolism and impaired ventriculo-arterial coupling, worse RV diastolic function, lower RV contractility, diminished RV contractility with exercise, and RV dilation with exercise. Metabolite profiles outperformed NT-proBNP in modeling RV contractility, diastolic function, and exercise performance. Specific metabolite profiles correspond to RV functional measurements only obtainable via invasive pressure-volume loop analysis and predict RV responses to exercise. Metabolic profiling may inform discovery of RV functional biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.
- Author
-
Launay, David, Montani, David, Hassoun, Paul M., Cottin, Vincent, Le Pavec, Jérôme, Clerson, Pierre, Sitbon, Olivier, Jaïs, Xavier, Savale, Laurent, Weatherald, Jason, Sobanski, Vincent, Mathai, Stephen C., Shafiq, Majid, Cordier, Jean-François, Hachulla, Eric, Simonneau, Gérald, and Humbert, Marc
- Subjects
- *
PULMONARY hypertension , *SYSTEMIC scleroderma , *PHENOTYPES , *HEMODYNAMICS , *INTERSTITIAL lung diseases , *PATIENTS , *HYPERTENSION risk factors - Abstract
Pre-capillary pulmonary hypertension (PH) in systemic sclerosis (SSc) is a heterogeneous condition with an overall bad prognosis. The objective of this study was to identify and characterize homogeneous phenotypes by a cluster analysis in SSc patients with PH. Patients were identified from two prospective cohorts from the US and France. Clinical, pulmonary function, high-resolution chest tomography, hemodynamic and survival data were extracted. We performed cluster analysis using the k-means method and compared survival between clusters using Cox regression analysis. Cluster analysis of 200 patients identified four homogenous phenotypes. Cluster C1 included patients with mild to moderate risk pulmonary arterial hypertension (PAH) with limited or no interstitial lung disease (ILD) and low DLCO with a 3-year survival of 81.5% (95% CI: 71.4–88.2). C2 had pre-capillary PH due to extensive ILD and worse 3-year survival compared to C1 (adjusted hazard ratio [HR] 3.14; 95% CI 1.66–5.94; p = 0.0004). C3 had severe PAH and a trend towards worse survival (HR 2.53; 95% CI 0.99–6.49; p = 0.052). Cluster C4 and C1 were similar with no difference in survival (HR 0.65; 95% CI 0.19–2.27, p = 0.507) but with a higher DLCO in C4. PH in SSc can be characterized into distinct clusters that differ in prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. GROUND-GLASS OPACITIES IN GROUP 1 PULMONARY HYPERTENSION: FINDINGS FROM THE PVDOMICS STUDY.
- Author
-
PADMANABHAN MENON, DIVYA, FRANTZ, ROBERT P, RISCHARD, FRANZ P, HASSOUN, PAUL M, GOCHANOUR, BENJAMIN, MATHAI, STEPHEN C, HILL, NICHOLAS S, HEMNES, ANNA R, EMANUEL FINET, J., LEMPEL, JASON, FARHA, SAMAR, WAXMAN, AARON B, HORN, EVELYN M, RENAPURKAR, RAHUL, GRUNIG, GABRIELE, CEM ERZURUM, SERPIL, BORLAUG, BARRY, and DUBROCK, HILARY M
- Subjects
- *
PULMONARY hypertension - Published
- 2023
- Full Text
- View/download PDF
33. Insulin-like growth factor binding Protein-4: A novel indicator of pulmonary arterial hypertension severity and survival.
- Author
-
Torres, Guillermo, Jun Yang, Griffiths, Megan, Brandal, Stephanie, Damico, Rachel, Vaidya, Dhananjay, Simpson, Catherine E., Pauciulo, Michael W., Nichols, William C., Ivy, David D., Austin, Eric D., Hassoun, Paul M., and Everett, Allen D.
- Subjects
- *
SOMATOMEDIN , *PULMONARY arterial hypertension , *INSULIN-like growth factor-binding proteins , *CARRIER proteins - Abstract
Proteomic analysis of patients with pulmonary arterial hypertension (PAH) has demonstrated significant abnormalities in the insulin-like growth factor axis (IGF). This study proposed to establish associations between a specific binding protein, insulin-like growth factor binding protein 4 (IGFBP4), and PAH severity as well as survival across varying study cohorts. In all cohorts studied, serum IGFBP4 levels were significantly elevated in PAH compared to controls (p < 0.0001). IGFBP4 concentration was also highest in the connective tissue-associated PAH (CTD-PAH) and idiopathic PAH subtypes (876 and 784 ng/mL, median, respectively). After adjustment for age and sex, IGFBP4 was significantly associated with worse PAH severity as defined by a decreased 6-min walk distance (6MWD), New York heart association functional class (NYHA-FC), REVEAL 2.0 score and higher right atrial pressures. In longitudinal analysis provided by one of the study cohorts, IGFBP4 was prospectively significantly associated with a shorter 6MWD, worse NYHA-FC classification, and decreased survival. Cox multivariable analysis demonstrated higher serum IGFBP4 as an independent predictor of survival in the overall PAHB cohort. Therefore, this study established that higher circulating IGFBP4 levels were significantly associated with worse PAH severity, decreased survival and disease progression. Dysregulation of IGF metabolism/growth axis may play a significant role in PAH cardio-pulmonary pathobiology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension
- Author
-
Piccari, Lucilla, Allwood, Brian, Antoniou, Katerina, Chung, Jonathan H., Hassoun, Paul M., Nikkho, Sylvia M., Saggar, Rajan, Shlobin, Oksana A., Vitulo, Patrizio, Nathan, Steven D., and Wort, Stephen John
- Subjects
- *
IDIOPATHIC pulmonary fibrosis , *INTERSTITIAL lung diseases , *DRUG development , *PULMONARY fibrosis , *CONNECTIVE tissue diseases , *PULMONARY emphysema , *PULMONARY hypertension - Abstract
Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD). Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in association with many other forms of ILD. Associated pathogenetic mechanisms are complex and incompletely understood but there is evidence of disruption of molecular and genetic pathways, with panvascular histopathologic changes, multiple pathophysiologic sequelae, and profound clinical ramifications. While there are some recognized clinical phenotypes such as combined pulmonary fibrosis and emphysema and some possible phenotypes such as connective tissue disease associated with ILD and PH, the identification of further phenotypes of PH in ILD has thus far proven elusive. This statement reviews the current evidence on the pathogenesis, recognized patterns, and useful diagnostic tools to detect phenotypes of PH in ILD. Distinct phenotypes warrant recognition if they are characterized through either a distinct presentation, clinical course, or treatment response. Furthermore, we propose a set of recommendations for future studies that might enable the recognition of new phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
- Author
-
Hassoun, Paul M., Mouthon, Luc, Barberà, Joan A., Eddahibi, Saadia, Flores, Sonia C., Grimminger, Friedrich, Jones, Peter Lloyd, Maitland, Michael L., Michelakis, Evangelos D., Morrell, Nicholas W., Newman, John H., Rabinovitch, Marlene, Schermuly, Ralph, Stenmark, Kurt R., Voelkel, Norbert F., Yuan, Jason X.-J., and Humbert, Marc
- Subjects
- *
PULMONARY hypertension , *INFLAMMATION , *VASCULAR endothelial growth factors , *MACROPHAGES , *DENDRITIC cells , *CLINICAL trials - Abstract
Inflammatory processes are prominent in various types of human and experimental pulmonary hypertension (PH) and are increasingly recognized as major pathogenic components of pulmonary vascular remodeling. Macrophages, T and B lymphocytes, and dendritic cells are present in the vascular lesions of PH, whether in idiopathic pulmonary arterial hypertension (PAH) or PAH related to more classical forms of inflammatory syndromes such as connective tissue diseases, human immunodeficiency virus (HIV), or other viral etiologies. Similarly, the presence of circulating chemokines and cytokines, viral protein components (e.g., HIV-1 Nef), and increased expression of growth (such as vascular endothelial growth factor and platelet-derived growth factor) and transcriptional (e.g., nuclear factor of activated T cells or NFAT) factors in these patients are thought to contribute directly to further recruitment of inflammatory cells and proliferation of smooth muscle and endothelial cells. Other processes, such as mitochondrial and ion channel dysregulation, seem to convey a state of cellular resistance to apoptosis; this has recently emerged as a necessary event in the pathogenesis of pulmonary vascular remodeling. Thus, the recognition of complex inflammatory disturbances in the vascular remodeling process offers potential specific targets for therapy and has recently led to clinical trials investigating, for example, the use of tyrosine kinase inhibitors. This paper provides an overview of specific inflammatory pathways involving cells, chemokines and cytokines, cellular dysfunctions, growth factors, and viral proteins, highlighting their potential role in pulmonary vascular remodeling and the possibility of future targeted therapy. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
36. Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease.
- Author
-
Hassoun, Paul M. and Krishnan, Jerry A.
- Subjects
- *
LETTERS to the editor , *PULMONARY hypertension - Abstract
A letter to the editor is presented in response to the article "Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease" by Mark T. Gladwin and colleagues in the February 26, 2007 issue.
- Published
- 2004
- Full Text
- View/download PDF
37. Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography.
- Author
-
Mercurio, Valentina, Hassan, Hussein J., Naranjo, Mario, Cuomo, Alessandra, Mazurek, Jeremy A., Forfia, Paul R., Balasubramanian, Aparna, Simpson, Catherine E., Damico, Rachel L., Kolb, Todd M., Mathai, Stephen C., Hsu, Steven, Mukherjee, Monica, and Hassoun, Paul M.
- Subjects
- *
PULMONARY arterial hypertension , *ECHOCARDIOGRAPHY , *PULMONARY hypertension - Abstract
Background: Given the morbidity and mortality associated with pulmonary arterial hypertension (PAH), risk stratification approaches that guide therapeutic management have been previously employed. However, most patients remain in the intermediate-risk category despite initial therapy. Herein, we sought to determine whether echocardiographic parameters could improve the risk stratification of intermediate-risk patients. Methods: Prevalent PAH patients previously enrolled in observational studies at 3 pulmonary hypertension centers were included in this study. A validated PAH risk stratification approach was used to stratify patients into low-, intermediate-, and high-risk groups. Right ventricular echocardiographic parameters were used to further stratify intermediate-risk patients into intermediate-low- and intermediate-high-risk groups based on transplant-free survival. Results: From a total of 146 patients included in our study, 38 patients died over a median follow-up of 2.5 years. Patients with intermediate-/high-risk had worse echocardiographic parameters. Tricuspid annular plane systolic excursion (TAPSE) and the degree of tricuspid regurgitation (TR) were highly associated with survival (p < 0.01, p = 0.04, respectively) and were subsequently used to further stratify intermediate-risk patients. Among intermediate-risk patients, survival was worse for patients with TAPSE < 19 mm compared to those with TAPSE ≥ 19 mm (estimated one-year survival 74% vs. 96%, p < 0.01) and for patients with moderate/severe TR compared to those with no/trace/mild TR (estimated one-year survival 70% vs. 93%, p < 0.01). Furthermore, among intermediate-risk patients, those with both TAPSE < 19 mm and moderate/severe TR had an estimated one-year survival (56%) similar to that of high-risk patients (56%), and those with both TAPSE ≥ 19 mm and no/trace/mild TR had an estimated one-year survival (97%) similar to that of low-risk patients (95%). Conclusions: Echocardiography, a routinely performed, non-invasive imaging modality, plays a pivotal role in discriminating distinct survival phenotypes among prevalent intermediate-risk PAH patients using TAPSE and degree of TR. This can potentially help guide subsequent therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Pulmonary Vascular Research Institute GoDeep: A meta‐registry merging deep phenotyping datafrom international PH reference centers.
- Author
-
Majeed, Raphael W., Wilkins, Martin R., Howard, Luke, Hassoun, Paul M., Anthi, Anastasia, Cajigas, Hector R., Cannon, John, Chan, Stephen Y., Damonte, Victoria, Elwing, Jean, Förster, Kai, Frantz, Robert, Ghio, Stefano, Al Ghouleh, Imad, Hilgendorff, Anne, Jose, Arun, Juaneda, Ernesto, Kiely, David G., Lawrie, Allan, and Orfanos, Stylianos E.
- Subjects
- *
PULMONARY arterial hypertension , *RESEARCH institutes , *AGE distribution , *DATA entry - Abstract
The Pulmonary Vascular Research Institute GoDeep meta‐registry is a collaboration of pulmonary hypertension (PH) reference centers across the globe. Merging worldwide PH data in a central meta‐registry to allow advanced analysis of the heterogeneity of PH and its groups/subgroups on a worldwide geographical, ethnical, and etiological landscape (ClinTrial. gov NCT05329714). Retrospective and prospective PH patient data (diagnosis based on catheterization; individuals with exclusion of PH are included as a comparator group) are mapped to a common clinical parameter set of more than 350 items, anonymized and electronically exported to a central server. Use and access is decided by the GoDeep steering board, where each center has one vote. As of April 2022, GoDeep comprised 15,742 individuals with 1.9 million data points from eight PH centers. Geographic distribution comprises 3990 enrollees (25%) from America and 11,752 (75%) from Europe. Eighty‐nine perecent were diagnosed with PH and 11% were classified as not PH and provided a comparator group. The retrospective observation period is an average of 3.5 years (standard error of the mean 0.04), with 1159 PH patients followed for over 10 years. Pulmonary arterial hypertension represents the largest PH group (42.6%), followed by Group 2 (21.7%), Group 3 (17.3%), Group 4 (15.2%), and Group 5 (3.3%). The age distribution spans several decades, with patients 60 years or older comprising 60%. The majority of patients met an intermediate risk profile upon diagnosis. Data entry from a further six centers is ongoing, and negotiations with >10 centers worldwide have commenced. Using electronic interface‐based automated retrospective and prospective data transfer, GoDeep aims to provide in‐depth epidemiological and etiological understanding of PH and its various groups/subgroups on a global scale, offering insights for improved management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Proteomics discovery of pulmonary hypertension biomarkers: Insulin‐like growth factor binding proteins are associated with disease severity.
- Author
-
Nies, Melanie K., Jun Yang, Griffiths, Megan, Damico, Rachel, Jie Zhu, Vaydia, Dhananjay, Zongming Fu, Brandal, Stephanie, Austin, Eric D., Ivy, Dunbar D., Hassoun, Paul M., Van Eyk, Jennifer E., and Everett, Allen D.
- Subjects
- *
INSULIN-like growth factor-binding proteins , *PROTEOMICS , *PULMONARY arterial hypertension , *BIOMARKERS , *FALSE discovery rate , *PULMONARY hypertension - Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by sustained elevations of pulmonary artery pressure. To date, we lack circulating, diagnostic, and prognostic markers that correlate to clinical and functional parameters. In this study, we performed mass spectrometry‐based proteomics analysis to identify circulating biomarkers of PAH. Plasma samples from patients with idiopathic pulmonary arterial hypertension (IPAH, N=9) and matched normal controls (N = 9) were digested with trypsin and analyzed using data‐dependent acquisition on an Orbitrap mass spectrometer. A total of 826 (false discovery rate [FDR] 0.047) and 461 (FDR 0.087) proteins were identified across all plasma samples obtained from IPAH and control subjects, respectively. Of these, 153 proteins showed >2 folds change (p < 0.05) between groups. Circulating levels of carbonic anhydrase 2 (CA2), plasma kallikrein (KLKB1), and the insulin‐like growth factor binding proteins (IGFBP1‐7) were quantified by immunoassay in an independent verification cohort (N=36 PAH and N = 35 controls). CA2 and KLKB1 were significantly different in PAH versus control but were not associated with any functional or hemodynamic measurements. Whereas, IGFBP1 and 2 were associated with higher pulmonary vascular resistance, IGFBP2, 4, and 7 with decreased 6‐min walk distance (6MWD), and IGFBP1, 2, 4, and 7 with worse survival. This plasma proteomic discovery analysis suggests the IGF axis may serve as important new biomarkers for PAH and play an important role in PAH pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Hepatoma‐derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival.
- Author
-
Yang, Jun, Ambade, Anjira S., Nies, Melanie, Griffiths, Megan, Damico, Rachel, Vaidya, Dhananjay, Brandal, Stephanie, Pauciulo, Michael W., Lutz, Katie A., Coleman, Anna W., Nichols, William C., Austin, Eric D., Ivy, Dunbar, Hassoun, Paul M., and Everett, Allen D.
- Subjects
- *
VASCULAR remodeling , *PULMONARY arterial hypertension , *CONNECTIVE tissues , *SMOOTH muscle , *PULMONARY artery , *PULMONARY hypertension - Abstract
Hepatoma‐derived growth factor (HDGF) was previously shown to be associated with increased mortality in a small study of idiopathic and connective tissue disease‐associated pulmonary arterial hypertension (PAH). In this study, we measured serum HDGF levels in a large multicenter cohort (total 2017 adult PAH‐Biobank enrollees), we analyzed the associations between HDGF levels and various clinical measures using linear or logistic regression models. Higher HDGF levels were found to be significantly associated with worse pulmonary hemodynamics, prostacyclin treatment; among PAH subtypes, higher HDGF levels were most associated with portopulmonary hypertension (beta = 0.469, p < 0.0001). Both Kaplan–Meier curve and Cox proportional hazard regression demonstrated that higher HDGF levels are associated with a higher risk of mortality (COX hazard ratio 1.31, p < 0.0001). Further, in the Sugen hypoxia (SuHx) rat model, the highest HDGF levels were post‐pulmonary circulation, and HDGF levels significantly increased with the development of PAH. In pulmonary arteries, immunohistochemistry staining showed that HDGF was highly expressed in pulmonary smooth muscle cells in both PAH patients and SuHx rats. In conclusion, we found that higher serum HDGF was linked with increased mortality, and associated with disease severity in a large multi‐center adult PAH cohort (n = 2017). In the SuHX PAH models, circulating HDGF levels are pulmonary in origin and increase with PAH progression. HDGF may be actively involved in vascular remodeling in PAH. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension.
- Author
-
Simpson, Catherine E., Kolb, Todd M., Hsu, Steven, Zimmerman, Stefan L., Corona‐Villalobos, Celia P., Mathai, Stephen C., Damico, Rachel L., and Hassoun, Paul M.
- Subjects
- *
PULMONARY arterial hypertension , *PULMONARY hypertension , *CARDIAC magnetic resonance imaging , *RECEIVER operating characteristic curves , *VASCULAR resistance - Abstract
Cardiac magnetic resonance (CMR) measures of right ventricular (RV) mass, volumes, and function have diagnostic and prognostic value in pulmonary arterial hypertension (PAH). We hypothesized that RV mass‐based metrics would discriminate incident PAH as redefined by the lower mean pulmonary arterial pressure (mPAP) threshold of >20 mmHg at the Sixth World Symposium on Pulmonary Hypertension (6th WSPH). Eighty‐nine subjects with suspected PAH underwent CMR imaging, including 64 subjects with systemic sclerosis (SSc). CMR metrics, including RV and left ventricular (LV) mass, were measured. All subjects underwent right heart catheterization (RHC) for assessment of hemodynamics within 48 h of CMR. Using generalized linear models, associations between CMR metrics and PAH were assessed, the best subset of CMR variables for predicting PAH were identified, and relationships between mass‐based metrics, hemodynamics, and other predictive CMR metrics were examined. Fifty‐nine subjects met 6th WSPH criteria for PAH. RV mass metrics, including ventricular mass index (VMI), demonstrated the greatest magnitude difference between subjects with versus without PAH. Overall and in SSc, VMI and RV mass measured by CMR were among the most predictive variables discriminating PAH at RHC, with areas under the receiver operating characteristic curve 0.86 and 0.83. respectively. VMI increased linearly with pulmonary vascular resistance and with mPAP in PAH, including in lower ranges of mPAP associated with mild PAH. VMI ≥ 0.37 yielded a positive predictive value of 90% for discriminating PAH. RV mass metrics measured by CMR, including VMI, discriminate incident, treatment‐naïve PAH as defined by 6th WSPH criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension.
- Author
-
Kolb, Todd M., Damico, Rachel L., and Hassoun, Paul M.
- Subjects
- *
PULMONARY hypertension , *TUMOR necrosis factors , *SMOOTH muscle , *MUSCLE cells , *INFLAMMATION , *GLUCOSE - Abstract
The article presents a study which provided evidence on the relationship between pulmonary arterial hypertension (PAH) and inflammation. It mentions that changes include alterations in apoptotic death sensitivity in the glucose metabolism of the pulmonary arterial smooth muscle cell (PASMC). It explores the study of Sutendra and colleagues which support the hypothesis that relates PASMC proliferation with inflammatory cytokine tumor necrosis factor alpha (TNFα).
- Published
- 2011
- Full Text
- View/download PDF
43. Xanthine oxidoreductase in respiratory and cardiovascular disorders.
- Author
-
Boueiz, Adel, Damarla, Mahendra, and Hassoun, Paul M.
- Subjects
- *
XANTHINE oxidase , *DEHYDROGENASES , *RESPIRATORY diseases , *CARDIOVASCULAR diseases , *OXIDATIVE stress , *OXIDATION-reduction reaction , *PURINES - Abstract
In addition to its critical role in purine metabolism, xanthine oxidoreductase (XOR) has been implicated in the development of tissue oxidative damage in a wide variety of respiratory and cardiovascular disorders such as acute lung injury, ischemia-reperfusion injury, atherosclerosis, heart failure, and arterial hypertension. Although much remains to be clarified about the regulation and signaling pathways of this enzyme, it is quite evident from abundant investigation in animal models and some human trials that XOR inhibition can favorably alter critical disease processes and impact outcomes. From promising bench-to-bedside data, a better understanding of this enigmatic enzyme is emerging. However, the positive findings related to XOR inhibition need to be confirmed in large-scale, well-designed clinical trials. This will hopefully provide new opportunities for therapeutic intervention. This article reviews the available evidence involving XOR in oxidative states with specific emphasis on respiratory and cardiovascular diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
44. PDE9A deficiency does not prevent chronic‐hypoxic pulmonary hypertension in mice.
- Author
-
Kolb, Todd M., Johnston, Laura, Damarla, Mahendra, Kass, David A., and Hassoun, Paul M.
- Subjects
- *
PULMONARY hypertension , *PULMONARY arterial hypertension , *CGMP-dependent protein kinase , *CYCLIC guanylic acid , *LABORATORY mice - Abstract
Inhibition of cyclic guanosine monophosphate (cGMP)‐specific phosphodiesterases (PDEs) is a cornerstone of pulmonary arterial hypertension (PAH)‐specific therapy. PDE9A, expressed in the heart and lung tissue, has the highest affinity for cGMP of all known PDEs. PDE9A deficiency protects mice against chronic left ventricular (LV) pressure overload via increased natriuretic peptide (NP)‐dependent cGMP signaling. Chronic‐hypoxic pulmonary hypertension (CH‐PH) is a model of chronic right ventricular (RV) pressure overload, and previous studies have demonstrated a protective role for NPs in the murine model. Therefore, we hypothesized that PDE9A deficiency would promote NP‐dependent cGMP signaling and prevent RV remodeling in the CH‐PH model, analogous to findings in the LV. We exposed wild‐type and PDE9A‐deficient (Pde9a−/−) C57BL/6 mice to CH‐PH for 3 weeks. We measured RV pressure, hypertrophy, and levels of lung and RV cGMP, PDE9A, PDE5A, and phosphorylation of the protein kinase G substrate VASP (vasodilatory‐stimulated phosphoprotein) after CH‐PH. In wild‐type mice, CH‐PH was associated with increased circulating ANP and lung PDE5A, but no increase in cGMP, PDE9A, or VASP phosphorylation. Downstream effectors of cGMP were not increased in Pde9a−/− mice exposed to CH‐PH compared with Pde9a+/+ littermates, and CH‐PH induced increases in RV pressure and hypertrophy were not attenuated in knockout mice. Taken together, these findings argue against a prominent role for PDE9A in the murine CH‐PH model. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Exercise right ventricular ejection fraction predicts right ventricular contractile reserve.
- Author
-
Ireland, Catherine G., Damico, Rachel L., Kolb, Todd M., Mathai, Stephen C., Mukherjee, Monica, Zimmerman, Stefan L., Shah, Ami A., Wigley, Fredrick M., Houston, Brian A., Hassoun, Paul M., Kass, David A., Tedford, Ryan J., and Hsu, Steven
- Subjects
- *
VENTRICULAR ejection fraction , *CARDIAC magnetic resonance imaging , *TREATMENT effectiveness , *EXERCISE tests , *CARDIAC catheterization - Abstract
Right ventricular (RV) contractile reserve shows promise as an indicator of occult RV dysfunction in pulmonary vascular disease. We investigated which measure of RV contractile reserve during exercise best predicts occult RV dysfunction and clinical outcomes. We prospectively studied RV contractile reserve in 35 human subjects referred for right heart catheterization for known or suspected pulmonary hypertension. All underwent cardiac magnetic resonance imaging, echocardiography, and supine invasive cardiopulmonary exercise testing with concomitant RV pressure-volume catheterization. Event-free survival was prospectively adjudicated from time of right heart catheterization for a 4-year follow-up period. RV contractile reserve during exercise, as measured by a positive change in end-systolic elastance (Ees) during exertion, was associated with elevation in pulmonary pressures but preservation of RV volumes. Lack of RV reserve, on the other hand, was tightly coupled with acute RV dilation during exertion (R2 = 0.76, p < 0.001). RV Ees and dilation changes each predicted resting RV-PA dysfunction. RV ejection fraction during exercise, which captured exertional changes in both RV Ees and RV dilation, proved to be a robust surrogate for RV contractile reserve. Reduced exercise RV ejection fraction best predicted occult RV dysfunction among a variety of resting and exercise RV measures, and was also associated with clinical worsening. RV ejection fraction during exercise, as an index of RV contractile reserve, allows for excellent identification of occult RV dysfunction, more so than resting measures of RV function, and may predict clinical outcomes as well. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.
- Author
-
Balasubramanian, Aparna, Kolb, Todd M., Damico, Rachel L., Hassoun, Paul M., McCormack, Meredith C., and Mathai, Stephen C.
- Subjects
- *
OBSTRUCTIVE lung diseases , *PROPORTIONAL hazards models , *PULMONARY artery , *PULMONARY function tests , *VASCULAR resistance , *PULMONARY hypertension , *CARDIAC catheterization , *PROGNOSIS , *ACQUISITION of data , *RETROSPECTIVE studies , *RESEARCH funding , *PULMONARY gas exchange - Abstract
Background: Patients with COPD who experience pulmonary hypertension (PH) have worse mortality than those with COPD alone. Predictors of poor outcomes in COPD-PH are not well-described. Diffusing capacity of the lung (Dlco) assesses the integrity of the alveolar-capillary interface and thus may be a useful prognostic tool among those with COPD-PH.Research Question: Using a single center registry, we sought to evaluate Dlco as a predictor of mortality in a cohort of patients with COPD-PH.Study Design and Methods: This retrospective cohort study analyzed 71 COPD-PH patients from the Johns Hopkins Pulmonary Hypertension Registry with right-sided heart catheterization (RHC)-proven PH and pulmonary function testing data within one year of diagnostic RHC. Transplant-free survival was calculated from index RHC. Adjusted transplant-free survival was modelled using Cox proportional hazard methods; age, pulmonary vascular resistance, FEV1, oxygen use, and N-terminal pro-brain natriuretic peptide were included as covariates.Results: Overall unadjusted transplant-free 1-, 3-, and 5-year survivals were 87%, 60%, and 51%, respectively. Survival was associated with reduced Dlco across the observed range of pulmonary artery pressures and pulmonary vascular resistance. Severe Dlco impairment was associated with poorer survival (log-rank χ2 13.07) (P < .001); adjusting for covariates, for every percent predicted decrease in Dlco, mortality rates increased by 4% (hazard ratio, 1.04; 95% CI, 1.01-1.07).Interpretation: Among patients with COPD-PH, severe gas transfer impairment is associated with higher mortality, even with adjustment for airflow obstruction and hemodynamics, which suggests that Dlco may be a useful prognostic marker in this population. Future studies are needed to further investigate the association between Dlco and morbidity and to determine the utility of Dlco as a biomarker for disease risk and severity in COPD-PH. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
47. Novel Mutations and Decreased Expression of the Epigenetic Regulator in Pulmonary Arterial Hypertension.
- Author
-
Potus, François, Pauciulo, Michael W., Cook, Elina K., Na Zhu, Hsieh, Alexander, Welch, Carrie L., Yufeng Shen, Tian, Lian, Lima, Patricia, Mewburn, Jeffrey, D'Arsigny, Christine L., Lutz, Katie A., Coleman, Anna W., Damico, Rachel, Snetsinger, Brooke, Martin, Ashley Y., Hassoun, Paul M., Nichols, William C., Chung, Wendy K., and Rauh, Michael J.
- Abstract
Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy. Hereditary cases are associated with germline mutations in BMPR2 and 16 other genes; however, these mutations occur in <25% of patients with idiopathic PAH and are rare in PAH associated with connective tissue diseases. Preclinical studies suggest epigenetic dysregulation, including altered DNA methylation, promotes PAH. Somatic mutations of Tet-methylcytosine-dioxygenase-2 (TET2), a key enzyme in DNA demethylation, occur in cardiovascular disease and are associated with clonal hematopoiesis, inflammation, and adverse vascular remodeling. The role of TET2 in PAH is unknown.Methods: To test for a role of TET2, we used a cohort of 2572 cases from the PAH Biobank. Within this cohort, gene-specific rare variant association tests were performed using 1832 unrelated European patients with PAH and 7509 non-Finnish European subjects from the Genome Aggregation Database (gnomAD) as control subjects. In an independent cohort of 140 patients, we quantified TET2 expression in peripheral blood mononuclear cells. To assess causality, we investigated hemodynamic and histological evidence of PAH in hematopoietic Tet2-knockout mice.Results: We observed an increased burden of rare, predicted deleterious germline variants in TET2 in PAH patients of European ancestry (9/1832) compared with control subjects (6/7509; relative risk=6; P=0.00067). Assessing the whole cohort, 0.39% of patients (10/2572) had 12 TET2 mutations (75% predicted germline and 25% somatic). These patients had no mutations in other PAH-related genes. Patients with TET2 mutations were older (71±7 years versus 48±19 years; P<0.0001), were more unresponsive to vasodilator challenge (0/7 versus 140/1055 [13.2%]), had lower pulmonary vascular resistance (5.2±3.1 versus 10.5±7.0 Wood units; P=0.02), and had increased inflammation (including elevation of interleukin-1β). Circulating TET2 expression did not correlate with age and was decreased in >86% of PAH patients. Tet2-knockout mice spontaneously developed PAH, adverse pulmonary vascular remodeling, and inflammation, with elevated levels of cytokines, including interleukin-1β. Long-term therapy with an antibody targeting interleukin-1β blockade resulted in regression of PAH.Conclusions: PAH is the first human disease related to potential TET2 germline mutations. Inherited and acquired abnormalities of TET2 occur in 0.39% of PAH cases. Decreased TET2 expression is ubiquitous and has potential as a PAH biomarker. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
48. Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.
- Author
-
Samokhin, Andriy O., Hsu, Steven, Yu, Paul B., Waxman, Aaron B., Alba, George A., Wertheim, Bradley M., Hopkins, C. Danielle, Bowman, Frederick, Channick, Richard N., Nikolic, Ivana, Faria-Urbina, Mariana, Hassoun, Paul M., Leopold, Jane A., Tedford, Ryan J., Ventetuolo, Corey E., Leary, Peter J., and Maron, Bradley A.
- Subjects
- *
BRAIN natriuretic factor , *PULMONARY hypertension , *PROLIFERATIVE vitreoretinopathy , *PROPORTIONAL hazards models , *VASCULAR resistance , *VENTRICULAR ejection fraction , *CONNECTIVE tissue diseases - Abstract
Pulmonary arterial hypertension (PAH) is a highly morbid disease characterized by elevated pulmonary vascular resistance (PVR) and pathogenic right ventricular remodeling. Endothelial expression of the prometastatic protein NEDD9 is increased in fibrotic PAH arterioles, and NEDD9 inhibition decreases PVR in experimental PAH. We hypothesized that circulating NEDD9 is increased in PAH and informs the clinical profile of patients. Clinical data and plasma samples were analyzed retrospectively for 242 patients from 5 referral centers (2010–2017): PAH (n = 139; female 82%, 58 [48–67] years), non-PAH pulmonary hypertension (PH) (n = 54; female 56%, 63.4 ± 12.2 years), and dyspnea non-PH controls (n = 36; female 75%, 54.2 ± 14.0 years). Compared with controls, NEDD9 was increased in PAH by 1.82-fold (p < 0.0001). Elevated NEDD9 correlated with PVR in idiopathic PAH (ρ = 0.42, p < 0.0001, n = 54), connective tissue disease (CTD)-PAH (ρ = 0.53, p < 0.0001, n = 53), and congenital heart disease–PAH (ρ = 0.68, p < 0.0001, n = 10). In CTD-PAH, NEDD9 correlated with 6-minute walk distance (ρ = −0.35, p = 0.028, n = 39). In contrast to the PAH biomarker N-terminal pro-brain natriuretic peptide (n = 38), NEDD9 correlated inversely with exercise pulmonary artery wedge pressure and more strongly with right ventricular ejection fraction (ρ = −0.41, p = 0.006, n = 45) in a mixed population. The adjusted hazard ratio for lung transplant–free survival was 1.12 (95% confidence interval [CI], 1.02–1.22, p = 0.01) and 1.75 (95% CI, 1.12–2.73, p = 0.01) per 1 ng/ml and 5 ng/ml increase in plasma NEDD9, respectively, by Cox proportional hazard model. In PAH, plasma NEDD9 is increased and associates with key prognostic variables. Prospective studies that include hard end points are warranted to validate NEDD9 as a novel PAH biomarker. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
49. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension.
- Author
-
Mullin, Christopher J., Khair, Rubina M., Damico, Rachel L., Kolb, Todd M., Hummers, Laura K., Hassoun, Paul M., Steen, Virginia D., and Mathai, Stephen C.
- Subjects
- *
CONFIDENCE intervals , *PEPTIDE hormones , *PULMONARY hypertension , *RISK assessment , *SURVIVAL analysis (Biometry) , *SYSTEMIC scleroderma , *DESCRIPTIVE statistics - Abstract
Objective: A prognostic equation and risk score calculator derived from the Registry to Evaluate Early and Long‐term Pulmonary Arterial Hypertension Disease Management (REVEAL) are being used to predict 1‐year survival in patients with pulmonary arterial hypertension (PAH), but little is known about the performance of these REVEAL survival prediction tools in systemic sclerosis (SSc)–associated PAH (SSc‐PAH). Methods: Prospectively gathered data from the Johns Hopkins Pulmonary Hypertension Program and Pulmonary Hypertension Assessment and Recognition of Outcome in Scleroderma Registries were used to evaluate the predictive accuracy of the REVEAL models for predicting the probability of 1‐year survival in patients with SSc‐PAH. Model discrimination was assessed by comparison of the Harrell's C‐index, model fit was assessed using multivariable regression techniques, and model calibration was assessed by comparing predicted to observed survival estimates. Results: The validation cohort consisted of 292 SSc‐PAH patients with a 1‐year survival rate of 87.4%. The C‐index for predictive accuracy of the REVEAL prognostic equation (0.734, 95% confidence interval [95% CI] 0.652–0.816) and for the risk score (0.743, 95% CI 0.663–0.823) demonstrated good discrimination, comparable to that in the model development cohort. The calibration slope was 0.707 (95% CI 0.400–1.014), indicating that the overall model fit was marginal (P = 0.06). The magnitude of risk assigned to low distance on the 6‐minute walk test (6MWD) and elevated serum levels of brain natriuretic peptide (BNP) was lower in the validation cohort than was originally seen in the REVEAL derivation cohort. Model calibration was poor, particularly for the highest risk groups. Conclusion: In predicting 1‐year survival in patients newly diagnosed as having SSc‐PAH, the REVEAL prognostic equation and risk score provide very good discrimination but poor calibration. REVEAL prediction scores should be interpreted with caution in newly diagnosed SSc‐PAH patients, particularly those with higher predicted risk of poor 1‐year survival resulting from a low 6MWD or a high BNP serum level. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. Pulmonary Circulation: Diseases and their Treatment.
- Author
-
Hassoun, Paul M.
- Subjects
- *
PULMONARY circulation , *NONFICTION - Abstract
Reviews the book "Pulmonary Circulation: Diseases and Their Treatment," by Andrew J. Peacock and Lewis J. Rubin.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.